Olema Pharmaceuticals (OLMA) Cash & Equivalents (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Cash & Equivalents data on file, last reported at $52.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $52.5 million, up 3.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.5 million (up 3.77% YoY), and the FY2025 annual result was $48.3 million, down 65.37% from the prior year.
• Cash & Equivalents rose to $52.5 million in Q1 2026 per OLMA's latest filing, from $48.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $139.5 million in Q4 2024 and troughed at $16.9 million in Q2 2024.
• A 5-year average of $48.4 million and a median of $35.9 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 338.02% in 2023, then tumbled 69.43% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $23.7 million in 2022, then soared by 189.17% to $68.5 million in 2023, then soared by 103.5% to $139.5 million in 2024, then slumped by 65.37% to $48.3 million in 2025, then climbed by 8.79% to $52.5 million in 2026.
• Business Quant data shows OLMA's Cash & Equivalents at $52.5 million in Q1 2026, $48.3 million in Q4 2025, and $35.3 million in Q3 2025.